AviadoBio Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
57
- Latest Deal Type
-
Later Stage VC
- Investors
-
13
AviadoBio General Information
Description
Developer of transformative gene therapies designed to transform people living with devastating neurodegenerative diseases. The company's platform combines a focus on diseases such as frontotemporal dementia and amyotrophic lateral sclerosis with a deep understanding of the brain and a suite of proprietary gene therapies to overcome the challenges of delivering the right drug to the right place, enabling patients to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases.
Contact Information
Website
www.aviadobio.comCorporate Office
- 20 Water Street
- London E14 5GX
- England, United Kingdom
Corporate Office
- 20 Water Street
- London E14 5GX
- England, United Kingdom
AviadoBio Timeline
AviadoBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 31-Mar-2026 | Completed | Clinical Trials - Phase 2 | |||
| 5. Accelerator/Incubator | 01-Jan-2026 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series B) | 08-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 31-Aug-2023 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 16-Sep-2020 | $15.8M | $15.8M | Completed | Startup | |
| 1. University Spin-Out | 20-Dec-2019 | Completed | Startup |
AviadoBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B Preferred | ||||||||
| Series B Preferred | ||||||||
| Series A Preferred | 54,012,081 | $0.000013 | $1.45 | $1.45 | 1x | $1.45 | 60.58% | |
| Series Seed preferred | 12,000,000 | $0.000013 | $1.32 | $1.32 | 1x | $1.32 | 13.46% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
AviadoBio Comparisons
Industry
Financing
Details
AviadoBio Competitors (62)
One of AviadoBio’s 62 competitors is Orchard Therapeutics, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| GenSight Biologics | Formerly VC-backed | Paris, France | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY | ||||
| Neurogene | Formerly VC-backed | New York, NY | ||||
| T3D Therapeutics | Venture Capital-Backed | Durham, NC |
AviadoBio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AviadoBio Patents
AviadoBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026215842-A1 | Compositions and methods for administration of therapeutic agents to the central nervous system | Pending | 09-Apr-2025 | ||
| WO-2026154123-A1 | Compositions and methods for treating neurological diseases | Pending | 17-Jan-2025 | ||
| WO-2025126153-A2 | Compositions and methods for treating sod1-mediated neurological diseases | Inactive | 14-Dec-2023 | ||
| AU-2024401157-A1 | Compositions and methods for treating sod1-mediated neurological diseases comprising inhibitory nucleic acids | Pending | 14-Dec-2023 | ||
| EP-4824257-A2 | Compositions and methods for treating sod1-mediated neurological diseases comprising inhibitory nucleic acids | Pending | 14-Dec-2023 | C12N15/1137 |
AviadoBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AviadoBio Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alzheimers Drug Discovery Foundation | Not-For-Profit Venture Capital | Minority | ||
| THE ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION | Corporation | Minority | ||
| Tech Nation Group | Accelerator/Incubator | |||
| Astellas Pharma | Corporation | Minority | ||
| EQT Life Sciences | Venture Capital | Minority |
AviadoBio FAQs
-
When was AviadoBio founded?
AviadoBio was founded in 2019.
-
Where is AviadoBio headquartered?
AviadoBio is headquartered in London, United Kingdom.
-
What is the size of AviadoBio?
AviadoBio has 57 total employees.
-
What industry is AviadoBio in?
AviadoBio’s primary industry is Drug Discovery.
-
Is AviadoBio a private or public company?
AviadoBio is a Private company.
-
What is AviadoBio’s current revenue?
The current revenue for AviadoBio is .
-
How much funding has AviadoBio raised over time?
AviadoBio has raised $149M.
-
Who are AviadoBio’s investors?
Alzheimers Drug Discovery Foundation, THE ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION, Tech Nation Group, Astellas Pharma, and EQT Life Sciences are 5 of 13 investors who have invested in AviadoBio.
-
Who are AviadoBio’s competitors?
Orchard Therapeutics, GenSight Biologics, Prevail Therapeutics, Neurogene, and T3D Therapeutics are some of the 62 competitors of AviadoBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
